Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
Abstract Number: 621 • 2016 ACR/ARHP Annual Meeting
Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Catalin Codreanu¹, Klara Sirova², Katerina Jarosova³ and Anastas Batalov⁴, ¹Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Revmatologie, Revmatologie MU Dr. Klara Sirova, sro, Ostrava, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Medical University of Plovdiv, UMHAT Kaspela, Plovdiv, Bulgaria
Background/Purpose: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, the high…
Abstract Number: 1613 • 2016 ACR/ARHP Annual Meeting
Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis
Christof Specker¹, Jörg Kaufmann², Herbert Kellner³, Peter Kaestner⁴, Christoph Volberg⁵, Verena Braunewell⁶, Martin Aringer⁷, Maren Sieburg⁸, Lothar Meier⁹, Michael Hofmann¹⁰, Jan-Paul Flacke¹¹, Hans-Peter Tony¹² and Gerhard Fliedner¹³, ¹Rheumatology & Clinical Immunology, University Hospital Essen, Essen, Germany, ²Ambulant Centres for Rheumatology, Ludwigsfelde, Germany, ³Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁴Outpatient department of Rheumatology, MVZ Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Rheumazentrum Neuss, Neuss, Germany, ⁶Schwerpunktpraxis Rheumatologie, Moenchengladbach, Germany, ⁷Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, ⁸Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ⁹Gemeinschaftspraxis für Innere Medizin - Rheumatologie, Hofheim am Taunus, Germany, ¹⁰Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ¹¹Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Internal Med/Rheumatology, Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: The non-interventional study ICHIBAN was set up in 2010 to evaluate the effectiveness and safety of intravenously administered Tocilizumab (TCZ IV) in patients (pts)…
Abstract Number: 2519 • 2016 ACR/ARHP Annual Meeting
Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
Mediola Ismajli¹ and Maria J. Leandro², ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Title: Predictors of flare in rheumatoid arthritis patients treated preventively with rituximab: a prospective study using ultrasound and patient reported outcomes Background/Purpose: Rituximab (RTX) is…
Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Espen A. Haavardsholm¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde B. Hammer³, Till Uhlig⁴, Hallvard Fremstad⁵, Tor Magne Madland⁶, Åse S. Lexberg⁷, Hilde Haukeland⁸, Erik Rødevand⁹, Christian Høili¹⁰, Hilde Stray¹¹, Anne Noraas Bendvold¹², Inger Johanne Widding Hansen¹³, Gunnstein Bakland^14,15, Lena B. Nordberg¹, Siri Lillegraven¹, Désirée van der Heijde^1,16 and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁶Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁷Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁸Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁹Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ¹⁰Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, ¹¹Haugesund Rheumatism Hospital, Haugesund, Norway, ¹²The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, ¹³Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, ¹⁴Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, ¹⁵Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, ¹⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
Abstract Number: 14L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Joel M. Kremer¹, Edward C. Keystone², Paul Emery³, Heidi S. Camp⁴, Alan Friedman⁴, Li Wang⁴, Ahmed A. Othman⁴, Nasser Khan⁴ and Steven Jungerwirth⁴, ¹Albany Medical College, Albany, NY, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: The safety, efficacy, and dose response of ABT-494, a novel selective JAK1 inhibitor, were characterized vs placebo (PBO) in patients (pts) with moderately to…
Abstract Number: 605 • 2015 ACR/ARHP Annual Meeting
Monitoring of Epstein Barr Virus, Cytomegalovirus and Varicella Zooster Virus Load in Patients Receiving Tocilizumab for Rheumatoid Arthritis
cindy mourgues¹, cecile henquell², Zuzana Tatar³, Bruno Pereira⁴, cynthia nourisson⁵, Anne Tournadre⁶, Martin Soubrier⁷ and Marion Couderc⁷, ¹puy de dome, CHU gabriel montpied clermont ferrand, clermont ferrand, France, ²virology, CHU gabriel montpied virology, clermont ferrand, France, ³Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁴Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁵rheumatology, chu gabriel montpied, clermont ferrand, France, ⁶Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Tocilizumab (TCZ) is an interleukin 6 (IL-6) inhibitor that is used in Rheumatoid Arthritis (RA) treatment (1). Due to the role played by IL-6…
Abstract Number: 1614 • 2015 ACR/ARHP Annual Meeting
The Impact of High Risk Susceptible Gene LILRA3 on Joint Inflammation in Rheumatoid Arthritis
Mengru Liu¹, Yan Du², Jing Zhang¹, Fanlei Hu¹, Li Zheng³, Yingni Li³, Jianping Guo¹ and Z. Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ³Peking University People's Hospital, Beijing, China
Background/Purpose: Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a putatively secreted protein belongs to the leukocyte immunoglobulin-like receptor (LILR) family. Based on our research that LILRA3…
Abstract Number: 2661 • 2015 ACR/ARHP Annual Meeting
Assessing Information Needs for Chronic Disease Management in Rheumatoid Arthritis
Marylou Cardenas-Turanzas¹, Elsa Gonzalez², Maithili Shethia¹, Maria A. Lopez-Olivo³, Pratibha Nayak⁴ and Maria E. Suarez-Almazor³, ¹Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Higher Education Administration, Texas A&M University, Corpus Christi, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴National Institutes of Health, Atlanta, GA
Background/Purpose: Patients with chronic disease are increasingly using social networking to share experiences about their disease, and receive peer support. As part of an educational…
Abstract Number: 7 • 2015 ACR/ARHP Annual Meeting
Influence of TNF on Anti-Inflammatory Tyrosine-Hydroxylase-Positive Synovial Cells in Rheumatoid Arthritis and Osteoarthritis
Zsuzsa Jenei-Lanzl, Markus Herrmann and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: In recent studies we demonstrated that catecholamines produced by tyrosine-hydroxylase-positive (TH+) synovial cells are able to mediate anti-inflammatory effects in rheumatoid arthritis (RA).a TNF…
Abstract Number: 608 • 2015 ACR/ARHP Annual Meeting
Safety of Surgery in Patients with Rheumatoid Arthritis Treated By Abatacept: Data from the French Orencia in Rheumatoid Arthritis (ORA) Registry
Augustin Latourte¹, Jacques Gottenberg², Cécile Luxembourger³, Isabelle Pane⁴, Pascal Claudepierre⁵, Pascal Richette¹, Pierre Lafforgue⁶, Philippe Ravaud⁴, BG Combe⁷, Alain G. Cantagrel³, Jean Sibilia⁸, Rene-Marc Flipo⁹, Philippe Gaudin¹⁰, Olivier Vittecoq¹¹, Thierry Schaeverbeke¹², Maxime Dougados¹³, Francis Berenbaum¹⁴, Jérémie Sellam¹⁵, Xavier Mariette¹⁶ and Raphaèle Seror¹⁷, ¹Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ²Rheumatology, Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁴Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France, ⁵Rheumatology, Université Paris Est Créteil, Créteil, France, ⁶Rheumatology, APHM, Aix Marseille University, Marseille, France, ⁷Rhumatologie, Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹⁰Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ¹¹University Hospital, Rouen, France, ¹²Rheumatology Department, Bordeaux Hospital, Bordeaux, France, ¹³Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ¹⁴Rheumatology, Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ¹⁵Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ¹⁷Rheumatology, AP-HP Bicêtre Hospital / Paris-Sud University, Le Kremlin-Bicêtre, France
Background/Purpose: The aim of this study was to investigate the frequency and risk factors of postoperative complications in rheumatoid arthritis (RA) patients treated with abatacept…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
Abstract Number: 2664 • 2015 ACR/ARHP Annual Meeting
Flares Occur Frequently in RA Patients Undergoing Arthroplasty
Susan M. Goodman¹, Rivka Friedlander², Caroline Figgie², Anh Hoang¹, Kathleen Andersen³, Alessandra B. Pernis⁴, Cristina T. Rozo⁵, Edward F. DiCarlo⁶, Mark P. Figgie⁷, Laura T. Donlin⁸ and VP Bykerk³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Research, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁵535 East 70th Street, Hospital for Special Surgery, New York, NY, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁷Orthopaedics, Hospital for Special Surgery, New York, NY, ⁸Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: RA patients are at risk for disease worsening (flare) after joint surgery, as medication is withdrawn to mitigate infection risk. We aimed to describe…
Abstract Number: 48 • 2015 ACR/ARHP Annual Meeting
Polypharmacy Is a Predictor of Hospitalisation in Patients with Rheumatoid Arthritis
Maria Filkova¹, Joao Carvalho¹, Sam Norton², David L. Scott¹, Tim Mant³, Andrew P. Cope¹, Mariam Molokhia⁴ and James Galloway¹, ¹Academic Department of Rheumatology, King´s College London, London, United Kingdom, ²Department of Psychological Medicine, King´s College London, London, United Kingdom, ³Quintiles Drug Research Unit at Guy's Hospital, London, London, United Kingdom, ⁴Division of Health and Social Care Research, King´s College London, London, United Kingdom
Background/Purpose: Multimorbidity is a major problem in rheumatoid arthritis (RA) but is difficult to measure. Polypharmacy (PP) - co-prescribing an individual multiple medications – is…
Abstract Number: 615 • 2015 ACR/ARHP Annual Meeting
Rituximab Non Responders Fail to Down Regulated CD19 on Naive B Cells
Hans-Peter Brezinschek¹, Florentine Fürst-Moazedi¹, Sonja Kielhauser², Martin Stradner³ and Winfried Graninger⁴, ¹Internal Medicine/Division of Rheumatology, Medical University Graz, Graz, Austria, ²Internal Medicine/Division of Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: CD19 is a membrane glycoprotein of the immunoglobulin superfamily and part of the hetero-oligomeric complex comprising the complement receptor type 2, which positively regulates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].